Boehringer Bails On Hanmi Lung Cancer Deal

Oct 03, 2016

Pulse News (Korea)

 

Boehringer Ingelheim has decided to return the exclusive license of Olmutinib, a lung cancer treatment candidate, back to Korea-based Hanmi Pharma.

 

In July 2015, Boehringer signed an exclusive license agreement with Hanmi Pharm to develop a third-generation EGFR drug to treat EGFR mutation positive lung cancer. The $730 million deal included a $50 million upfront fee paid to Hanmi, plus milestones up to $680 million.

 

According to news sources, Boehringer Ingelheim halted trials and decided that Olmutinib could not compete with its rival AstraZeneca’s Tagrisso. According to reporting from PharmaLive, Hanmi indicated  in a filing that Boehringer Ingelheim ended the deal after two patients died because of a serious skin reaction. 

 

 

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments